UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

British journal of haematology, 2021-03, Vol.192 (6), p.1026-1030

2021

Link zum Volltext

Verfügbarkeit prüfen

Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy

Leukemia research, 2024-01, Vol.136, p.107429-107429, Article 107429

2024

Link zum Volltext

Verfügbarkeit prüfen

Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic

Leukemia & lymphoma, 2022-09, Vol.63 (11), p.2731-2734

2022

Link zum Volltext

Verfügbarkeit prüfen

Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML

Blood, 2015-04, Vol.125 (18), p.2815-2824

2015

Link zum Volltext

Verfügbarkeit prüfen

Salvaging AML with CLAG: Novel option, or more of the same?

Leukemia research, 2011-03, Vol.35 (3), p.297-298

2011

Link zum Volltext

Verfügbarkeit prüfen

Primed for the kill: occupying Bcl-2 to target death in acute myeloid leukaemia

Biodiscovery, 2012-12, Vol.6 (6), p.1-4

2012

Link zum Volltext

Verfügbarkeit prüfen

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.1453-1455

2022

Link zum Volltext

Verfügbarkeit prüfen

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.1261-1261

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Blood, 2021-11, Vol.138 (Supplement 1), p.3675-3675

2021

Link zum Volltext

Verfügbarkeit prüfen

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

Blood, 2018-11, Vol.132 (Supplement 1), p.1426-1426

2018

Link zum Volltext

Verfügbarkeit prüfen

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Blood, 2019-11, Vol.134 (Supplement_1), p.2648-2648

2019

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression

Blood, 2015-12, Vol.126 (23), p.3457-3457

2015

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib-based antibody depletion for refractory autoimmune hematological diseases

Blood advances, 2016-11, Vol.1 (1), p.31-35

2016

Link zum Volltext

Verfügbarkeit prüfen

Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting

Blood, 2014-12, Vol.124 (21), p.988-988

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5283: Elucidating a novel role for inositol polyphosphate 4-phosphatase type II (INPP4B) in mediating chemoresistance in acute myeloid leukemia

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5283-5283

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Hematology
(9)
Life Sciences & Biomedicine
(9)
Science & Technology
(9)
Humans
(7)
Leukemia, Myeloid, Acute - Drug Therapy
(7)
Leukemia
(5)
Oncology
(5)
Acute Myeloid Leukemia
(3)
Aml
(3)
Venetoclax
(3)
Adult
(2)
Aged
(2)
Animals
(2)
Antineoplastic Agents - Pharmacology
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Apoptosis
(2)
Bcl-2 Protein
(2)
Cancer
(2)
Chemotherapy
(2)
Female
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription

Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy

Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic

Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML

Salvaging AML with CLAG: Novel option, or more of the same?

Primed for the kill: occupying Bcl-2 to target death in acute myeloid leukaemia

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression

Bortezomib-based antibody depletion for refractory autoimmune hematological diseases

Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting

Abstract 5283: Elucidating a novel role for inositol polyphosphate 4-phosphatase type II (INPP4B) in mediating chemoresistance in acute myeloid leukemia

Suchergebnisse filtern